Shionogi & Co

Shionogi & Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Shionogi & Co (4507.T) as of Oct 15, 2026 is 97.05 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 104.63 % — a change of -7.25% (lower).

FCF Conversion

97.05 %

YoY

-7.25%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Shionogi & Co is 2026 97.05 % . FCF Conversion Rate (FCF/EBITDA) of Shionogi & Co was 2025 104.63 % . It decreases by -7.25% lower compared to the previous year.

The Shionogi & Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
119.35 JPY
Jan 1, 2020
98.35 JPY
Jan 1, 2021
68.03 JPY
Jan 1, 2022
61.75 JPY
Jan 1, 2023
76.06 JPY
Jan 1, 2024
87.39 JPY
Jan 1, 2025
104.63 JPY
Jan 1, 2026
97.05 JPY
The Shionogi & Co FCF Conversion history
YEARFCF ConversionYoY
97.05 %-7.25%
104.63 %+19.74%
87.39 %+14.89%
76.06 %+23.18%
61.75 %-9.24%
68.03 %-30.83%
98.35 %-17.60%
119.35 %+4.86%
113.82 %-5.91%
120.97 %-14.28%
141.13 %+77.84%
79.36 %-54.24%
173.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shionogi & Co Stock analysis

What does Shionogi & Co do? The company Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. It was founded in 1878 and has since become a significant player in the industry. It currently employs over 6,000 employees worldwide and is listed on the Tokyo Stock Exchange. Shionogi is divided into several business segments that offer different products and services. The largest segment is the pharmaceutical division, which specializes in the development and marketing of drugs. The company has strong expertise in infectious diseases, pain management, and oncology, and operates in many countries worldwide. One flagship product is the antibiotic Cefditoren, used to treat various bacterial infections. In addition to the pharmaceutical division, Shionogi is also active in other areas. For example, the company offers diagnostic and laboratory services, operating multiple labs in Japan and other countries. Another business segment is the production and marketing of nutritional supplements, sold in Japan, China, and the USA. Shionogi's business model is based on extensive research and development, as well as strong brand positioning. The company invests a significant portion of its revenue each year in the research and development of new drugs and better treatment options for existing diseases. Thanks to the high quality of its products and strong brand, the company has a loyal customer base. In recent years, Shionogi has focused on international expansion opportunities and has expanded its activities in various regions. For example, it has partnered with US pharmaceutical company Purdue Pharma to develop and market a novel pain medication. Shionogi's annual revenue is around 1.5 billion euros. The company is particularly strong in Japan and other Asian countries, but is also active in the US and Europe. In the coming years, Shionogi aims to further expand its international business and solidify its position as a significant player in the industry. Key focuses will be on the launch of new products and finding treatments for previously incurable diseases. Overall, Shionogi is an innovative and successful company that utilizes its expertise in the pharmaceutical industry in various ways. With its dedicated employees and strong brand, it will continue to play an important role in the industry. Shionogi & Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shionogi & Co stock

FCF Conversion Rate (FCF/EBITDA) of Shionogi & Co is 97.05 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Shionogi & Co changed from 104.63 % to 97.05 %, representing a -7.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Shionogi & Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Shionogi & Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Shionogi & Co

All Key Metrics — Shionogi & Co